Cogstate Ltd (ASX: CGS) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Cogstate Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$361.98 million
P/E Ratio
26.51
Dividend Yield
0.87%
Shares Outstanding
171.55 million
Earnings per share
0.062
Dividend per share
0.02
Year To Date Return
-5.31%
Earnings Yield
3.77%
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Cogstate Ltd (ASX: CGS)
Latest News
Earnings Results
2 ASX All Ords stocks rocketing over 7% on strong results
Share Fallers
Why Clinuvel, Cogstate, Omni Bridgeway, and Westgold shares are sinking
Earnings Results
3 ASX All Ord shares being hammered on earnings today
Share Fallers
Why A2 Milk, Altium, Cogstate, and Ingenia shares are sinking today
Share Fallers
Why CogState, Downer, Temple & Webster, and Woodside shares are dropping
Opinions
These 2 small-cap ASX shares have soared, but a fund manager still tips them as buys
Healthcare Shares
2 ASX healthcare shares to buy that you've not heard of: expert
Technology Shares
Here's how ASX tech shares fared in September
Share Gainers
These were the 5 best-performing ASX All Ords shares in September
Share Gainers
Why Cogstate, Global Lithium, Premier, and Woodside shares are charging higher
Healthcare Shares
The Cogstate share price is rocketing again, up another 27% on Thursday
Share Gainers
Why Cogstate, Mayne Pharma, Race Oncology, and Whitehaven Coal are charging higher
Frequently Asked Questions
-
No, Cogstate does not pay dividends at this stage.
-
Cogstate Ltd listed on the ASX on 13 February 2004.
CGS ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Cogstate Ltd
Cogstate Ltd (ASX: CGS) is a neuroscience technology company specialising in brain health assessments. The principal activity of the company is the sale of technology and services to measure cognition.
The company provides licensed digital tests for health professionals and medical researchers. Its services include scientific consultancy, project management, data management, statistical analysis, and reporting. Cogstate generates the bulk of its revenue from its clinical trials segment.
Cogstate's technology has been used in more than 2,000 scientific and clinical trial studies. These include fields such as Alzheimer's, depression, and bipolar disorder research as well as studies investigating cognitive impairment in athletes as a result of concussive injuries.
CGS Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 06 Mar 2026 | $2.11 | $-0.07 | -3.21% | 62,969 | $2.15 | $2.17 | $2.10 |
| 05 Mar 2026 | $2.18 | $0.04 | 1.87% | 40,384 | $2.14 | $2.20 | $2.14 |
| 04 Mar 2026 | $2.14 | $0.00 | 0.00% | 56,460 | $2.13 | $2.16 | $2.12 |
| 03 Mar 2026 | $2.14 | $-0.05 | -2.28% | 71,811 | $2.20 | $2.20 | $2.13 |
| 02 Mar 2026 | $2.19 | $-0.10 | -4.37% | 163,393 | $2.35 | $2.35 | $2.11 |
| 27 Feb 2026 | $2.29 | $-0.02 | -0.87% | 39,857 | $2.31 | $2.35 | $2.26 |
| 26 Feb 2026 | $2.31 | $-0.06 | -2.53% | 132,918 | $2.37 | $2.37 | $2.24 |
| 25 Feb 2026 | $2.37 | $0.17 | 7.73% | 88,242 | $2.28 | $2.37 | $2.22 |
| 24 Feb 2026 | $2.20 | $0.02 | 0.92% | 431,345 | $2.24 | $2.24 | $2.19 |
| 23 Feb 2026 | $2.18 | $0.01 | 0.46% | 147,794 | $2.27 | $2.30 | $2.15 |
| 20 Feb 2026 | $2.17 | $-0.20 | -8.44% | 97,226 | $2.37 | $2.37 | $2.17 |
| 19 Feb 2026 | $2.37 | $0.19 | 8.72% | 47,679 | $2.32 | $2.37 | $2.14 |
| 18 Feb 2026 | $2.18 | $-0.02 | -0.91% | 284,068 | $2.18 | $2.30 | $2.18 |
| 17 Feb 2026 | $2.20 | $0.07 | 3.29% | 15,522 | $2.12 | $2.20 | $2.12 |
| 16 Feb 2026 | $2.13 | $-0.04 | -1.84% | 124,066 | $2.14 | $2.20 | $2.11 |
| 13 Feb 2026 | $2.17 | $0.05 | 2.36% | 47,612 | $2.10 | $2.17 | $2.07 |
| 12 Feb 2026 | $2.12 | $-0.13 | -5.78% | 48,115 | $2.23 | $2.32 | $2.12 |
| 11 Feb 2026 | $2.25 | $0.09 | 4.17% | 856,126 | $2.16 | $2.25 | $2.15 |
| 10 Feb 2026 | $2.16 | $-0.01 | -0.46% | 97,777 | $2.15 | $2.16 | $2.10 |
| 09 Feb 2026 | $2.17 | $0.02 | 0.93% | 129,377 | $2.12 | $2.18 | $2.03 |
| 06 Feb 2026 | $2.15 | $-0.01 | -0.46% | 112,069 | $2.11 | $2.15 | $2.04 |
| 05 Feb 2026 | $2.16 | $-0.02 | -0.92% | 21,973 | $2.16 | $2.16 | $2.12 |
| 04 Feb 2026 | $2.18 | $-0.01 | -0.46% | 15,799 | $2.17 | $2.19 | $2.12 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 15 Dec 2025 | Kim Wenn | Buy | 10,183 | $22,259 |
On-market trade.
|
| 31 Oct 2025 | Bradley O'Connor | Issued | 591,822 | $1,047,525 |
Issue of securities. Performance Rights: 1,512,073
|
| 17 Oct 2025 | Bradley O'Connor | Sell | 338,429 | $824,591 |
On-market trade.
|
| 17 Oct 2025 | Bradley O'Connor | Exercise | 399,500 | $312,409 |
Exercise of options.
|
| 17 Oct 2025 | Bradley O'Connor | Buy | 399,500 | $312,409 |
Exercise of options.
|
| 09 Sep 2025 | Martyn Myer | Sell | 2,500,000 | $4,425,000 |
Off-market trade.
|
| 09 Sep 2025 | Martyn Myer | Buy | 2,500,000 | $4,200,000 |
Off-market trade.
|
| 03 Sep 2025 | Richard Mohs | Buy | 13,000 | $22,524 |
On-market trade.
|
| 01 Sep 2025 | Bradley O'Connor | Expiry | 500,000 | $850,000 |
Options expired.
|
| 29 Aug 2025 | Bradley O'Connor | Buy | 50,327 | $87,485 |
On-market trade.
|
| 09 Jul 2025 | Bradley O'Connor | Exercise | 850,500 | $665,091 |
Exercise of options.
|
| 09 Jul 2025 | Bradley O'Connor | Issued | 850,500 | $665,091 |
Exercise of options.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Martyn Kenneth Myer | Non-Executive ChairmanNon-Executive Director | Oct 1999 |
Mr Myer is Chair of the Doherty Institute at the University of Melbourne and the board of the Australian Chamber Orchestra. He previously served as Deputy Chancellor of the Council of the University of Melbourne, President of The Myer Foundation, one of two principle Myer Family philanthropic funds, President of the Howard Florey Institute of Experimental Physiology and Medicine and was a director of The Florey Institute of Neuroscience and Mental Health, where he participated in the transition of the Institutes research focus towards diagnostic and therapeutic neuroscience, including a focus on degenerative brain diseases. He is a member of the Risk and Compliance Committee.
|
| Mr Bradley O'Connor | Chief Executive OfficerManaging Director | Nov 2005 |
Mr O Connor has responsibility for Cogstates overall strategic direction and day to day operations as well as the development of expansion opportunities outside of the core clinical trials business. Prior to taking the position of Chief Executive Officer at Cogstate in 2005, he joined Cogstate as Chief Financial Officer and Company Secretary in 2004. Prior to that, he held senior positions at Spherion Group, Australian Wine Exchange and PricewaterhouseCoopers. He is a member of the Risk and Compliance Committee
|
| Ms Ingrid Anne Player | Non-Executive Director | Aug 2019 |
Ms Player brings healthcare sector experience and commercial expertise to the Board of Cogstate. She has held senior executive roles with Healthscope Ltd, a leading private healthcare provider in Australia, including the former positions of Group Executive Legal, Governance and Sustainability, and General Counsel and Company Secretary from 2005 until 2019. She also has considerable international commercial and regulatory experience that spans different markets and industries, which she gained in private legal practice in Australia and in The Netherlands. Ms Player holds a Bachelor of Economics & Bachelor of Laws (Hons) from Monash University. She is a graduate member of the Australian Institute of Company Directors. He is chairman of the Risk and Compliance Committee.
|
| Dr Richard Mohs | Non-Executive Director | Jan 2017 |
Dr Mohs is currently Chief Scientific Officer for the Global Alzheimers Platform (GAP) Foundation, a non profit devoted to enhancing the speed and quality of Alzheimers disease research. He also serves as a consultant to academic institutions, foundations and biopharmaceutical companies, and is a member of the Board of Governors for the Alzheimers Drug Discovery Foundation. He retired from Eli Lilly in 2015, where he held leadership positions including Vice President for Neuroscience Early Clinical Development and Leader of the Global Alzheimers Drug Development Team. Before joining Eli Lilly, Dr Mohs spent 23 years with the Mount Sinai School of Medicine where he was Professor in the Department of Psychiatry and Associate Chief of Staff for Research at the Bronx Veterans Affairs Medical Centre. He is a member of the Risk and Compliance Committee.
|
| Ms Kim Wenn | Non-Executive Director | Nov 2020 |
Ms Wenn is an experienced board director who brings technology experience and strong commercial expertise to the Board of Cogstate, with over 30 years of experience in innovation roles. Her experience includes, among other things, business strategy, governance and change management with a focus on digital disruption. Ms Wenn holds a Bachelor of Computer Science from Monash University and completed an Advanced Management Program from Harvard University. She is a member of the Risk and Compliance Committee.
|
| Mr David James Franks | Company Secretary | Feb 2021 |
-
|
| Ms Kristi Geddes | Joint Company Secretary | Apr 2023 |
-
|
| Darren Watson | Chief Financial Officer |
-
|
|
| Pam Ventola | Chief Science Officer |
-
|
|
| David James Franks | Company Secretary |
-
|
|
| Rachel Colite | Executive Vice President Clinical Trials |
-
|
|
| Kristi Geddes | Joint Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| HSBC Custody Nominees | 36,096,848 | 21.40% |
| Dagmar Dolby Fund | 25,732,802 | 15.20% |
| Myer & Myer Pty Ltd | 14,424,569 | 8.50% |
| Citicorp Nominees Pty Limited | 14,408,375 | 8.50% |
| Anacacia Pty Limited | 14,009,827 | 8.30% |
| J P Morgan Nominees Australia | 10,087,159 | 6.00% |
| Mpyer Investments Pty Ltd | 6,061,872 | 3.60% |
| Mr Bradley John O'Connor | 4,488,429 | 2.70% |
| Beta Gamma Pty Ltd | 3,420,000 | 2.00% |
| David Dolby Investments Ii Llc | 2,834,838 | 1.70% |
| Myer & Myer Pty Ltd 1 | 2,313,000 | 1.40% |
| HSBC Custody Nominees 1 | 1,536,998 | 0.90% |
| Kenneth Ryan Billard | 1,500,000 | 0.90% |
| Mr Alistair David Strong | 1,320,000 | 0.80% |
| Bnp Paribas Nominees Pty Ltd | 1,057,276 | 0.60% |
| BNP Paribas Nominees Pty Ltd 1 | 1,014,307 | 0.60% |
| Mr David Alexander Simpson & | 999,699 | 0.60% |
| BNP Paribas Noms | 936,844 | 0.60% |
| Ronnocob Pty Ltd | 917,173 | 0.50% |
| Irsf Pty Limited | 800,000 | 0.50% |